INSTITUT GUSTAVE ROUSSY

Their core work

Institut Gustave Roussy is one of Europe's leading comprehensive cancer centers, based near Paris. They conduct translational and clinical cancer research spanning oncology drug development, tumor immunology, and precision medicine. Their work bridges laboratory discoveries — from tumor microbiome signatures to immunoprofiling — directly into large-scale clinical trials. They also contribute to pediatric oncology, radiation protection research, and international efforts to standardize health data and microbiome science.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Gustave Roussy focused on foundational cancer biology — tumor resistance mechanisms (TKI resistance), pediatric preclinical models (ITCC-P4), breast cancer screening (MyPeBS), and training networks in immunotherapy. From 2019 onward, their work shifted decisively toward the cancer microbiome (ONCOBIOME, IHMCSA), immune checkpoint therapy profiling (IMMUcan), and data-driven clinical trial design (CCE_DART). The most recent project (SPeR-ToNE, 2022) in cardiovascular research suggests early-stage diversification beyond oncology.

Gustave Roussy is moving from classical tumor biology toward microbiome-based diagnostics and immune profiling, positioning itself at the intersection of oncology, data science, and personalized treatment prediction.

How they like to work

Gustave Roussy operates predominantly as an active partner (14 of 17 projects), contributing specialized clinical and translational expertise to large European consortia. With 251 unique partners across 27 countries, they function as a well-connected hub rather than a closed network. When they do coordinate (3 projects), they take on scientifically ambitious roles — their largest coordinated project (ONCOBIOME, EUR 2.9M) is also their most funded, showing they lead where they have deep domain authority.

Gustave Roussy has collaborated with 251 unique partners across 27 countries, making them one of the most broadly networked cancer research centers in H2020. Their partnerships span all of Western Europe and extend into widening countries like Lithuania (TREL).

What sets them apart

Gustave Roussy combines the clinical infrastructure of a major cancer treatment center with deep research capabilities in emerging fields like the cancer microbiome — a combination few European institutions can match. Their coordination of ONCOBIOME (the largest EU-funded study linking gut microbiome to cancer outcomes) gives them a first-mover advantage in microbiome-guided oncology. For consortium builders, they bring both patient cohort access and translational research capacity, making them a high-value partner for any cancer-related proposal.

Highlights from their portfolio

• ONCOBIOME
  Largest project by far (EUR 2.9M), coordinated by Gustave Roussy — a landmark study connecting gut microbiome signatures to cancer incidence, prognosis, and treatment response across five cancer types.
• MyPeBS
  Major international randomized trial comparing personalized, risk-stratified breast cancer screening to standard approaches — directly impacts public health screening policy across Europe.
• SPeR-ToNE
  Their most recent coordinated project (2022) and a notable departure from oncology into cardiovascular research on spermidine and hypertension, signaling scientific diversification.